Is Clearpoint Neuro Stock a Good Investment?
Clearpoint Neuro Investment Advice | CLPT |
- Examine Clearpoint Neuro's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Clearpoint Neuro's leadership team and their track record. Good management can help Clearpoint Neuro navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Clearpoint Neuro's business and its evolving consumer preferences.
- Compare Clearpoint Neuro's performance and market position to its competitors. Analyze how Clearpoint Neuro is positioned in terms of product offerings, innovation, and market share.
- Check if Clearpoint Neuro pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Clearpoint Neuro's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Clearpoint Neuro stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Clearpoint Neuro is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Clearpoint Neuro Stock
Researching Clearpoint Neuro's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 33.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.7. Clearpoint Neuro last dividend was issued on the 27th of July 2016. The entity had 1:40 split on the 27th of July 2016.
To determine if Clearpoint Neuro is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Clearpoint Neuro's research are outlined below:
| Clearpoint Neuro generated a negative expected return over the last 90 days | |
| Clearpoint Neuro has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 31.39 M. Net Loss for the year was (18.91 M) with profit before overhead, payroll, taxes, and interest of 19.12 M. | |
| Clearpoint Neuro currently holds about 45.14 M in cash with (8.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84. |
Clearpoint Neuro uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Clearpoint Neuro. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Clearpoint Neuro's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Clearpoint Neuro's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 375.8 M.Clearpoint Neuro's profitablity analysis
The company has Profit Margin (PM) of (0.6) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.72) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.72.Determining Clearpoint Neuro's profitability involves analyzing its financial statements and using various financial metrics to determine if Clearpoint Neuro is a good buy. For example, gross profit margin measures Clearpoint Neuro's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Clearpoint Neuro's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Clearpoint Neuro's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Clearpoint Neuro. Check Clearpoint Neuro's Beneish M Score to see the likelihood of Clearpoint Neuro's management manipulating its earnings.
Basic technical analysis of Clearpoint Stock
As of the 19th of March, Clearpoint Neuro shows the mean deviation of 3.49, and Risk Adjusted Performance of 0.0019. Clearpoint Neuro technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Clearpoint Neuro's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Clearpoint Neuro insiders, such as employees or executives, is commonly permitted as long as it does not rely on Clearpoint Neuro's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Clearpoint Neuro insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Clearpoint Neuro's Outstanding Corporate Bonds
Clearpoint Neuro issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Clearpoint Neuro uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Clearpoint bonds can be classified according to their maturity, which is the date when Clearpoint Neuro has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Clearpoint Neuro's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Clearpoint Neuro's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0019 | |||
| Market Risk Adjusted Performance | (0.21) | |||
| Mean Deviation | 3.49 | |||
| Coefficient Of Variation | (13,797) | |||
| Standard Deviation | 5.16 | |||
| Variance | 26.6 | |||
| Information Ratio | 0.0096 | |||
| Jensen Alpha | (0.03) | |||
| Total Risk Alpha | 0.5204 | |||
| Treynor Ratio | (0.22) | |||
| Maximum Drawdown | 39.95 | |||
| Value At Risk | (6.50) | |||
| Potential Upside | 6.25 | |||
| Skewness | 0.8466 | |||
| Kurtosis | 6.77 |
| Risk Adjusted Performance | 0.0019 | |||
| Market Risk Adjusted Performance | (0.21) | |||
| Mean Deviation | 3.49 | |||
| Coefficient Of Variation | (13,797) | |||
| Standard Deviation | 5.16 | |||
| Variance | 26.6 | |||
| Information Ratio | 0.0096 | |||
| Jensen Alpha | (0.03) | |||
| Total Risk Alpha | 0.5204 | |||
| Treynor Ratio | (0.22) | |||
| Maximum Drawdown | 39.95 | |||
| Value At Risk | (6.50) | |||
| Potential Upside | 6.25 | |||
| Skewness | 0.8466 | |||
| Kurtosis | 6.77 |
Consider Clearpoint Neuro's intraday indicators
Clearpoint Neuro intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Clearpoint Neuro stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Clearpoint Neuro time-series forecasting models is one of many Clearpoint Neuro's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Clearpoint Neuro's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Clearpoint Stock media impact
Far too much social signal, news, headlines, and media speculation about Clearpoint Neuro that are available to investors today. That information is available publicly through Clearpoint media outlets and privately through word of mouth or via Clearpoint internal channels. However, regardless of the origin, that massive amount of Clearpoint data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Clearpoint Neuro news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Clearpoint Neuro relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Clearpoint Neuro's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Clearpoint Neuro alpha.
Clearpoint Neuro Corporate Management
| Mazin Sabra | Chief Officer | Profile | |
| Danilo DAlessandro | Chief Officer | Profile | |
| Ellisa JD | General Secretary | Profile | |
| Ellisa Cholapranee | General Secretary | Profile | |
| Jeremy Stigall | Executive Delivery | Profile | |
| Jacqueline Keller | Vice Marketing | Profile |
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.